vimarsana.com

Page 2 - ஜார்ஜ் ஹுவாங் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

An Important Collector Explains Why High Jewels Are The Best Investment

Scott Rudin s bad behavior was just another Hollywood cliche until a new generation said time s up

Scott Rudin s bad behavior was just another Hollywood cliche until a new generation said time s up
msn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from msn.com Daily Mail and Mail on Sunday newspapers.

Scott Rudin s bad behavior was just another Hollywood cliche, until a new generation said time s up

Scott Rudin s bad behavior was just another Hollywood cliche, until a new generation said time s up
washingtonpost.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from washingtonpost.com Daily Mail and Mail on Sunday newspapers.

Apexigen Announces Presentations Of Preclinical Data For Its TNFR2 Antagonist (APX601) And SIRPα Antagonist (APX701) Programs At The AACR Annual Meeting 2021

Apexigen Announces Presentations Of Preclinical Data For Its TNFR2 Antagonist (APX601) And SIRPα Antagonist (APX701) Programs At The AACR Annual Meeting 2021 News provided by Share this article Share this article SAN CARLOS, Calif., April 9, 2021 /PRNewswire/ Apexigen, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, today announced two upcoming poster presentations accepted as late breaking abstracts at the American Association for Cancer Research (AACR) Annual Meeting 2021, to be held virtually April 10-15, 2021. Details are as follows: Title of Presentation : APX601, a Potent TNFR2 Antagonist as a Novel and Promising Approach to Reverse Tumor Immune Suppression  (Abstract ID LB175)

SenseTime Receives CE Mark for its AI Medical Solution SenseCare-Chest DR Pro Diagnostic Software

SenseTime Receives CE Mark for its AI Medical Solution SenseCare-Chest DR Pro Diagnostic Software ABU DHABI, UAE, April 8, 2021 /PRNewswire/ SenseTime, the world-leading artificial intelligence (AI) company, announced that it has recently been granted CE mark approval for its AI medical solution SenseCare-Chest DR Pro. Leveraging SenseTime s cutting-edge AI technologies, the solution can quickly triage normal and abnormal scans from chest X-ray screening and accurately detect various chest diseases on the abnormal ones, effectively improving the efficiency of large-scale physical examination and regular clinical diagnosis. The CE marks means that the software can be commercialised across the European Union under the European Union Medical Device Regulation (MDR), as well as other markets where it is recognised. The certification of SenseCare-Chest DR Pro marks another milestone for SenseTime in introducing its AI medical solutions for both computed tomography (CT) and digital rad

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.